Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
Medtronic
Mallinckrodt
Harvard Business School

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; IRBESARTAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Hydrochlorothiazide; Irbesartan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00095394 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed Sanofi Phase 3 2004-09-01 The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095394 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed Bristol-Myers Squibb Phase 3 2004-09-01 The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed Sanofi Phase 3 2004-10-01 The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗ Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed Bristol-Myers Squibb Phase 3 2004-10-01 The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00110422 ↗ Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed Sanofi Phase 4 2005-11-01 The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrochlorothiazide; Irbesartan

Condition Name

Condition Name for Hydrochlorothiazide; Irbesartan
Intervention Trials
Hypertension 13
Healthy 1
Metabolic Syndrome 1
Microalbuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Irbesartan
Intervention Trials
Hypertension 12
Metabolic Syndrome 1
Malnutrition 1
Albuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrochlorothiazide; Irbesartan

Trials by Country

Trials by Country for Hydrochlorothiazide; Irbesartan
Location Trials
United States 71
Canada 18
Germany 6
Taiwan 4
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrochlorothiazide; Irbesartan
Location Trials
Texas 4
Pennsylvania 2
Louisiana 2
Maryland 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrochlorothiazide; Irbesartan

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Irbesartan
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Irbesartan
Clinical Trial Phase Trials
Completed 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrochlorothiazide; Irbesartan

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Irbesartan
Sponsor Trials
Sanofi 10
Bristol-Myers Squibb 4
Roxane Laboratories 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Irbesartan
Sponsor Trials
Industry 16
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
McKinsey
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.